168 related articles for article (PubMed ID: 8382293)
1. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present.
Mosser AG; Rueckert RR
J Virol; 1993 Mar; 67(3):1246-54. PubMed ID: 8382293
[TBL] [Abstract][Full Text] [Related]
2. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.
Mosser AG; Shepard DA; Rueckert RR
Arch Virol Suppl; 1994; 9():111-9. PubMed ID: 8032243
[TBL] [Abstract][Full Text] [Related]
3. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
[TBL] [Abstract][Full Text] [Related]
4. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin mutants.
Genovese D; Catone S; Farah ME; Gambacorta A; Fiore L
J Gen Virol; 1999 Jan; 80 ( Pt 1)():157-167. PubMed ID: 9934698
[TBL] [Abstract][Full Text] [Related]
5. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.
Fox MP; Otto MJ; McKinlay MA
Antimicrob Agents Chemother; 1986 Jul; 30(1):110-6. PubMed ID: 3019232
[TBL] [Abstract][Full Text] [Related]
6. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids.
Rombaut B; Andries K; Boeyé A
J Gen Virol; 1991 Sep; 72 ( Pt 9)():2153-7. PubMed ID: 1716654
[TBL] [Abstract][Full Text] [Related]
7. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
Shepard DA; Heinz BA; Rueckert RR
J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
[TBL] [Abstract][Full Text] [Related]
8. Cold-adapted poliovirus mutants bypass a postentry replication block.
Dove AW; Racaniello VR
J Virol; 1997 Jun; 71(6):4728-35. PubMed ID: 9151866
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of poliovirus uncoating by disoxaril (WIN 51711).
Zeichhardt H; Otto MJ; McKinlay MA; Willingmann P; Habermehl KO
Virology; 1987 Sep; 160(1):281-5. PubMed ID: 2820136
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of poliovirus uncoating efficiently block the early membrane permeabilization induced by virus particles.
Almela MJ; González ME; Carrasco L
J Virol; 1991 May; 65(5):2572-7. PubMed ID: 1850030
[TBL] [Abstract][Full Text] [Related]
12. Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus.
Danthi P; Tosteson M; Li QH; Chow M
J Virol; 2003 May; 77(9):5266-74. PubMed ID: 12692228
[TBL] [Abstract][Full Text] [Related]
13. Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis.
Diamond SE; Kirkegaard K
J Virol; 1994 Feb; 68(2):863-76. PubMed ID: 8289389
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of poliovirus uncoating in HeLa cells in a nonacidic environment.
Gromeier M; Wetz K
J Virol; 1990 Aug; 64(8):3590-7. PubMed ID: 2164587
[TBL] [Abstract][Full Text] [Related]
15. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
Burns CC; Shaw J; Campagnoli R; Jorba J; Vincent A; Quay J; Kew O
J Virol; 2006 Apr; 80(7):3259-72. PubMed ID: 16537593
[TBL] [Abstract][Full Text] [Related]
16. WIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface.
Wang W; Lee WM; Mosser AG; Rueckert RR
J Virol; 1998 Feb; 72(2):1210-8. PubMed ID: 9445020
[TBL] [Abstract][Full Text] [Related]
17. Guanidine-dependent mutants of poliovirus: identification of three classes with different growth requirements.
Pincus SE; Rohl H; Wimmer E
Virology; 1987 Mar; 157(1):83-8. PubMed ID: 3029969
[TBL] [Abstract][Full Text] [Related]
18. Guanidine-resistant poliovirus mutants produce modified 37-kilodalton proteins.
Anderson-Sillman K; Bartal S; Tershak DR
J Virol; 1984 Jun; 50(3):922-8. PubMed ID: 6328023
[TBL] [Abstract][Full Text] [Related]
19. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.
Dove AW; Racaniello VR
J Virol; 2000 Apr; 74(8):3929-31. PubMed ID: 10729171
[TBL] [Abstract][Full Text] [Related]
20. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
